EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Drastic Synergy of Lovastatin and Antrodia camphorata Extract Combination against PC3 Androgen-Refractory Prostate Cancer Cells, Accompanied by AXL and Stemness Molecules Inhibition

Chih-Jung Yao, Chia-Lun Chang, Ming-Hung Hu iD, Chien-Huang Liao, Gi-Ming Lai, Tzeon-Jye Chiou iD, Hsien-Ling Ho, Hui-Ching Kuo, Ya-Yu Yang, Jacqueline Whang-Peng, Shuang-En Chuang

Nutrients · 2023

DOI: 10.3390/nu15214493 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nutrients, 2023. Verfasst von Chih-Jung Yao und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Education and Research, Wan Fang Hospital, Taipei Medical University, Taipei 11696, Taiwan. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Biological Products. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health Research Institutes, Miaoli, Taiwan, Health and welfare surcharge of tobacco products, Taiwan, Research grant from Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prostate cancer (PC) is the second most frequently diagnosed cancer and the fifth leading cause of cancer-related death in males worldwide. Early-stage PC patients can benefit from surgical, radiation, and hormonal therapies; however, once the tumor transitions to an androgen-refractory state, the efficacy of treatments diminishes considerably. Recently, the exploration of natural products, particularly dietary phytochemicals, has intensified in response to addressing this prevailing medical challenge. In this study, we uncovered a synergistic effect from combinatorial treatment with lovastatin (an active component in red yeast rice) and Antrodia camphorata (AC, a folk mushroom) extract against PC3 human androgen-refractory PC cells. This combinatorial modality resulted in cell cycle arrest at the G0/G1 phase and induced apoptosis, accompanied by a marked reduction in molecules responsible for cellular proliferation (p-Rb/Rb, Cyclin A, Cyclin D1, and CDK1), aggressiveness (AXL, p-AKT, and survivin), and stemness (SIRT1, Notch1, and c-Myc). In contrast, treatment with either AC or lovastatin alone only exerted limited impacts on the cell cycle, apoptosis, and the aforementioned signaling molecules. Notably, significant reductions in canonical PC stemness markers (CD44 and CD133) were observed in lovastatin/AC-treated PC3 cells. Furthermore, lovastatin and AC have been individually examined for their anti-PC properties. Our findings elucidate a pioneering discovery in the synergistic combinatorial efficacy of AC and clinically viable concentrations of lovastatin on PC3 PC cells, offering novel insights into improving the therapeutic effects of dietary natural products for future strategic design of therapeutics against androgen-refractory prostate cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsBiological ProductsCell ProliferationMaleLovastatinPolyporalesAndrogensApoptosisPC-3 CellsHumansCell Line, Tumor

Stichwörter der Autor:innen

AXLAntrodia camphorataPC3lovastatinprostate cancer

Substanzen

AndrogensLovastatinBiological Products

Autor:innen und Institutionen

  • Department of Medical Education and Research, Wan Fang Hospital, Taipei Medical University, Taipei 11696, Taiwan.
  • Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan.
  • Division of Hematology and Medical Oncology, Department of Internal Medicine, Wan Fang Hospital, Taipei Medical University, Taipei 11696, Taiwan.
  • Cancer Center, Wan Fang Hospital, Taipei Medical University, Taipei 11696, Taiwan.
  • National Institute of Cancer Research, National Health Research Institutes, Miaoli 35053, Taiwan.

ORCID-Profile: Ming-Hung Hu, Tzeon-Jye Chiou

Förderung

  • National Health Research Institutes, Miaoli, Taiwan
  • Health and welfare surcharge of tobacco products, Taiwan
  • Research grant from Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan
  • Health and Welfare Surcharge of Tobacco Products
  • Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan

Zitieren

APA

Yao, C. J., Chang, C. L., Hu, M. H., Liao, C. H., Lai, G. M., Chiou, T. J., Ho, H. L., Kuo, H. C., Yang, Y. Y., Whang-Peng, J., & Chuang, S. E. (2023). Drastic Synergy of Lovastatin and Antrodia camphorata Extract Combination against PC3 Androgen-Refractory Prostate Cancer Cells, Accompanied by AXL and Stemness Molecules Inhibition. Nutrients. https://doi.org/10.3390/nu15214493

Vancouver

Yao CJ, Chang CL, Hu MH, Liao CH, Lai GM, Chiou TJ, et al. Drastic Synergy of Lovastatin and Antrodia camphorata Extract Combination against PC3 Androgen-Refractory Prostate Cancer Cells, Accompanied by AXL and Stemness Molecules Inhibition. Nutrients. 2023. doi:10.3390/nu15214493

BibTeX
@article{Yao2023,
  author = {Yao, Chih-Jung and Chang, Chia-Lun and Hu, Ming-Hung and Liao, Chien-Huang and Lai, Gi-Ming and Chiou, Tzeon-Jye and Ho, Hsien-Ling and Kuo, Hui-Ching and Yang, Ya-Yu and Whang-Peng, Jacqueline and Chuang, Shuang-En},
  title = {Drastic Synergy of Lovastatin and Antrodia camphorata Extract Combination against PC3 Androgen-Refractory Prostate Cancer Cells, Accompanied by AXL and Stemness Molecules Inhibition},
  journal = {Nutrients},
  year = {2023},
  doi = {10.3390/nu15214493}
}
Kostenlos starten →